Updates are available Addendum dated 2025-06-26
Click to view Addendum: https://doi.org/10.1038/s41586-025-09282-7
Updates are available Correction dated 2025-12-12
Click to view Correction: https://doi.org/10.1038/s41586-025-09780-8
-
Authors
Varghese, Alan https://orcid.org/0000-0001-8052-1428
Gusarov, Ivan
Gamallo-Lana, Begoña
Dolgonos, Daria
Mankan, Yatin
Shamovsky, Ilya
Phan, Mydia
Jones, Rebecca https://orcid.org/0000-0002-5056-9292
Gomez-Jenkins, Maria https://orcid.org/0000-0003-3682-9219
White, Eileen https://orcid.org/0000-0003-2961-3065
Wang, Rui https://orcid.org/0000-0003-3825-3620
Jones, Drew R. https://orcid.org/0000-0001-8732-9818
Papagiannakopoulos, Thales https://orcid.org/0000-0002-2251-1624
Pacold, Michael E. https://orcid.org/0000-0003-3688-2378
Mar, Adam C.
Littman, Dan R. https://orcid.org/0000-0002-2850-8688
Nudler, Evgeny https://orcid.org/0000-0002-8811-3071
- License Information
-
More Information
Article History
Received: 14 November 2023
Accepted: 8 April 2025
First Online: 21 May 2025
Change Date: 30 July 2025
Change Type: Update
Change Details: This paper was originally published under Creative Commons Attribution 4.0 International license, CC-BY-NC-ND, © The Author(s). It is now available under a Creative Commons Attribution 4.0 International license, CC-BY, © The Author(s). The error has been corrected in the online version of the article.
Change Date: 12 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-09780-8
Competing interests
: D.R.L. consults for and has equity interest in Vedanta Bioscience, Sonoma Immunotherapeutics, Immunai, IMIDomics and Pfizer.
